EW
PMVP icon

Evoke Wealth’s PMV Pharmaceuticals PMVP Stock Holding History

Evoke Wealth’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$165K Hold
133,122
– – ﹤0.01% 685
2025
Q4 		$166K Hold
133,122
– – ﹤0.01% 650
2025
Q3 		$186K Hold
133,122
– – ﹤0.01% 620
2025
Q2 		$141K Hold
133,122
– – ﹤0.01% 576
2025
Q1 		$145K Hold
133,122
– – ﹤0.01% 435
2024
Q4 		$201K Hold
133,122
– – 0.01% 410
2024
Q3 		$198K Buy
133,122
+69,889
+111% +$108K 0.01% 397
2024
Q2 		$102K Buy
+63,233
New +$114K 0.12% 95
2023
Q1 		– Sell
-133,122
Closed -$1.16M – 370
2022
Q4 		$1.16M Hold
133,122
– – 0.04% 149
2022
Q3 		$1.58M Hold
133,122
– – 0.06% 115
2022
Q2 		$1.9M Buy
133,122
+101,208
+317% +$1.47M 0.07% 112
2022
Q1 		$664K Hold
31,914
– – 0.02% 205
2021
Q4 		$737K Buy
+31,914
New +$771K 0.02% 206
2021
Q3 		– Sell
-3,403
Closed -$116K – 1202
2021
Q2 		$116K Buy
+3,403
New +$114K ﹤0.01% 414

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Evoke Wealth's PMVP Position: Q1 2026 in Review

Evoke Wealth held its PMV Pharmaceuticals (PMVP) position steady in Q1 2026 at 133,122 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Evoke Wealth first reported a position in PMVP in Q2 2021 and has held it in 14 quarters since. The position peaked at $1.9M in Q2 2022. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Evoke Wealth held 133,122 shares of PMV Pharmaceuticals worth $165K as of Q1 2026.
  • Evoke Wealth left its PMV Pharmaceuticals share count unchanged in Q1 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of Evoke Wealth's portfolio in Q1 2026, its #685 holding.
  • Evoke Wealth first reported a position in PMV Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
  • Evoke Wealth's PMV Pharmaceuticals position peaked at $1.9M in Q2 2022.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Evoke Wealth's 13F filing for Q1 2026, filed 15 May 2026.